Impax Laboratories, a specialty pharmaceutical company,  has launched an authorized generic version of Solodyn (minocycline HCl) extended-release tablets, 65 mg and 115 mg.

Minocycline HCl extended-release tablets, 65 mg and 115 mg, had annual U.S. sales of approximately $148 million according to IQVIA for the 12 months ending December 2017.

Impax Laboratories, Inc. (Impax) is a specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of central nervous system disorder branded products. Impax markets its generic products through its Impax Generics division and markets its branded products through the Impax Specialty Pharma division. Additionally, where strategically appropriate, Impax develops marketing partnerships to fully leverage its technology platform and pursues partnership opportunities that offer alternative dosage form technologies, such as injectables, nasal sprays, inhalers, patches, creams, and ointments.